Media coverage
22
Media coverage
Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Morningstar.com Country/Territory United States Date 6/05/20 URL https://www.morningstar.com/news/globe-newswire/7915504/first-patients-dosed-in-phase-23-randomized-controlled-trial-of-mesoblasts-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet TMC Net Country/Territory United States Date 6/05/20 URL www.tmcnet.com/usubmit/-first-patients-dosed-phase-23-randomized-controlled-trial-/2020/05/06/9145294.htm Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 … Media name/outlet TMC Net Country/Territory United States Date 6/05/20 URL www.tmcnet.com/usubmit/2020/05/06/9145294.htm Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet MarketScreener.com Country/Territory United States Date 6/05/20 URL https://www.marketscreener.com/MESOBLAST-LIMITED-6499027/news/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVI-30547911/ Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet WVB Country/Territory United States Date 6/05/20 URL wvb.com/news/industry/view/id/8032256 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Market Newsdesk Country/Territory United States Date 6/05/20 URL www.marketnewsdesk.com/?p=262820 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast ’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Stockwatch Country/Territory Canada Date 6/05/20 URL www.stockwatch.com/News/Item?bid=U-z7915504-U%3aMESO-20200506&symbol=MESO®ion=U Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Markets Business Insider Country/Territory United States Date 6/05/20 URL www.quotenet.com/news/stocks/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome-1029169646 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Crwe World Country/Territory United States Date 6/05/20 URL crweworld.com/article/news-provided-by-globenewswire/1522117/first-patients-dosed-in-phase-23-randomized-controlled-trial-of-mesoblasts-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Customer Zone 360.com Country/Territory United States Date 6/05/20 URL www.customerzone360.com/news/2020/05/06/9145294.htm Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Jotup Country/Territory United States Date 6/05/20 URL https://jotup.co/node/765470 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Biotechgate Country/Territory Switzerland Date 6/05/20 URL www.biotechgate.com/gate/v3/news_details.php?news_id=200953&page_id=?next=1 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel l for COVID 19 Acute Respiratory Distress Syndrome Media name/outlet Market News Publishing Country/Territory United States Date 6/05/20 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet BioSpace Country/Territory United States Date 6/05/20 URL https://www.biospace.com/article/releases/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome/?s=95 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet FirstWord Pharma Country/Territory United States Date 6/05/20 URL www.firstwordpharma.com/node/1721807 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet GlobeNewswire Country/Territory United States Date 6/05/20 URL https://www.globenewswire.com/news-release/2020/05/06/2028234/0/en/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVID-19-Acute-Respiratory-Distress-Syndrome.html Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory ... Media name/outlet EIN Presswire Country/Territory United States Date 6/05/20 URL https://www.einpresswire.com/article/516330279/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet PrimeNewswire (Top News) Country/Territory United States Date 6/05/20 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet EIN News Country/Territory United States Date 6/05/20 URL https://www.einnews.com/pr_news/516330279/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblast-s-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast's Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet MarketScreener.com Country/Territory United States Date 6/05/20 URL https://www.marketscreener.com/MESOBLAST-LIMITED-6499027/news/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVI-30547911/?utm_medium=RSS&utm_content=20200506 Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet GlobeNewswire Country/Territory United States Date 6/05/20 URL www.globenewswire.com/news-release/2020/05/06/2028234/0/en/First-Patients-Dosed-in-Phase-2-3-Randomized-Controlled-Trial-of-Mesoblast-s-Remestemcel-l-for-COVID-19-Acute-Respiratory-Distress-Syndrome.html Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns Title First Patients Dosed in Phase 2/3 Randomized Controlled Trial of Mesoblast’s Remestemcel-l for COVID-19 Acute Respiratory Distress Syndrome Media name/outlet Global Banking & Finance Review Country/Territory United Kingdom Date 5/05/20 URL https://www.globalbankingandfinance.com/category/news/first-patients-dosed-in-phase-2-3-randomized-controlled-trial-of-mesoblasts-remestemcel-l-for-covid-19-acute-respiratory-distress-syndrome/ Persons Alan Moskowitz, Emilia Bagiella, Annetine Gelijns